Top

Published in:

01-12-2012 | Research Article

Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells

Authors: Yajie Zhang, Ruobing Xu, Guiqin Li, Xiaobin Xie, Jie Long, Hongyan Wang

Published in: Tumor Biology | Issue 6/2012

Abstract

The differentially expressed in adenocarcinoma of the lung-1 (DAL-1) protein is a member of the membrane-associated cytoskeleton protein 4.1 family. This protein was previously found to be downregulated or lost in more than half of primary non-small cell lung cancers (NSCLC). In this study, the relationship between DAL-1 expression and NSCLC metastasis was examined. DAL-1 mRNA and protein levels were measured in NSCLC cell lines and in tumor cells isolated from the pleural fluid of NSCLC patients clinically diagnosed with distant metastases to the bone or brain. The results revealed that DAL-1 expression was observed in two (GLC-82 and NCI-H460) out of seven metastatic NSCLC cell lines examined. DAL-1 expression was not observed in the cells isolated from the pleural fluid in nine out of ten patients. Overexpression of DAL-1 in A549 cells, a cell line lacking endogenous DAL-1, inhibited cell migration and invasion by approximately 38 and 48 %, respectively. In contrast, DAL-1 knockdown in NCI-H460 cells enhanced the migration and invasion potential of this cell line 4.6- and 3-fold, respectively. Furthermore, DAL-1 promoter methylation was observed in six of nine pleural fluid NSCLC cell isolates and in two cell lines (A549 and H1299), as evidenced by a lack of endogenous DAL-1. Demethylation in A549 cells successfully restored DAL-1 mRNA and protein expression levels, resulting in a parallel remarkable inhibition of migration and invasion. These results indicated that DAL-1 was pivotal in triggering NSCLC migration and invasion and that loss of DAL-1 expression was due to the epigenetic methylation.

Society AC (2011) Global cancer facts & figures, 2nd edn. New York: American Cancer Society.

D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v116–9. doi:10.1093/annonc/mdq189.PubMedCrossRef

Howlader N NA, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. editors. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute. http://seer.cancer.gov/csr/1975_2009_pops09/. 2012

Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003;3(1):55–63. doi:10.1038/nrc967.PubMedCrossRef

Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95. doi:10.1016/j.cell.2006.11.001.PubMedCrossRef

Ahmad A, Hart IR. Mechanisms of metastasis. Crit Rev Oncol Hematol. 1997;26(3):163–73. S1040-8428(97)10002-6.PubMedCrossRef

Veer LJ, van’t Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6. doi:10.1038/415530a.CrossRef

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009. doi:10.1056/NEJMoa021967.PubMedCrossRef

Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49–54. doi:10.1038/ng1060.PubMedCrossRef

10.

Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci. 1998;23(8):281–2.PubMedCrossRef

11.

Gautreau A, Poullet P, Louvard D, Arpin M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96(13):7300–5.PubMedCrossRef

12.

Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3(8):586–99. doi:10.1038/nrm882.PubMedCrossRef

13.

Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci. 2002;115(Pt 21):3991–4000.PubMedCrossRef

14.

Yu H, Zhang Y, Ye L, Jiang WG. The FERM family proteins in cancer invasion and metastasis. Front Biosci. 2011;16:1536–50.PubMedCrossRef

15.

Mani T, Hennigan RF, Foster LA, Conrady DG, Herr AB, Ip W. FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function. Mol Cell Biol. 2011;31(10):1983–96. doi:10.1128/MCB.00609-10.PubMedCrossRef

16.

Gunn-Moore FJ, Welsh GI, Herron LR, Brannigan F, Venkateswarlu K, Gillespie S, et al. A novel 4.1 ezrin radixin moesin (FERM)-containing protein, ‘Willin’. FEBS Lett. 2005;579(22):5089–94. doi:10.1016/j.febslet.2005.07.097.PubMedCrossRef

17.

Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999;59(1):35–43.PubMed

18.

Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer. 2002;100(2):181–8. doi:10.1002/ijc.10470.PubMedCrossRef

19.

Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis. 2001;8(2):266–78. doi:10.1006/nbdi.2000.0376.PubMedCrossRef

20.

Bernkopf DB, Williams ED. Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets. 2008;12(7):845–53. doi:10.1517/14728222.12.7.845.PubMedCrossRef

21.

Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000;9(10):1495–500.PubMedCrossRef

22.

Gimm JA, An X, Nunomura W, Mohandas N. Functional characterization of spectrin-actin-binding domains in 4.1 family of proteins. Biochemistry. 2002;41(23):7275–82.PubMedCrossRef

23.

Cavanna T, Pokorná E, Vesely P, Gray C, Zicha D. Evidence for protein 4.1B acting as a metastasis suppressor. Journal of Cell Science. 2007;120(4):606–16. doi:10.1242/jcs.000273.PubMedCrossRef

24.

Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.PubMedCrossRef

25.

Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163–7. doi:10.1038/5947.PubMedCrossRef

26.

Yamada D, Kikuchi S, Williams YN, Sakurai-Yageta M, Masuda M, Maruyama T, et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer. 2006;118(4):916–23. doi:10.1002/ijc.21450.PubMedCrossRef

27.

Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 2011. doi:10.1007/s12282-011-0272-7.

28.

Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, et al. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia. 2010;12(7):579–89.PubMed

29.

Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH. Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene. 2005;24(11):1946–57. doi:10.1038/sj.onc.1208335.PubMedCrossRef

30.

Gerber MA, Bahr SM, Gutmann DH. Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res. 2006;66(10):5295–303. doi:10.1158/0008-5472.CAN-05-1628.PubMedCrossRef

31.

Yu T, Robb VA, Singh V, Gutmann DH, Newsham IF. The 4.1/ezrin/radixin/moesin domain of the DAL-1/protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J. 2002;365(Pt 3):783–9. doi:10.1042/BJ20020060.PubMed

32.

Nunomura W, Takakuwa Y, Parra M, Conboy J, Mohandas N. Regulation of protein 4.1R, p55, and glycophorin C ternary complex in human erythrocyte membrane. J Biol Chem. 2000;275(32):24540–6. doi:10.1074/jbc.M002492200.PubMedCrossRef

33.

Busam RD, Thorsell AG, Flores A, Hammarstrom M, Persson C, Obrink B, et al. Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL-1/4.1B). J Biol Chem. 2011;286(6):4511–6. doi:10.1074/jbc.M110.174011.PubMedCrossRef

34.

Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta. 2001;1552(1):39–45.PubMed

35.

Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001;27(4):427–30. doi:10.1038/86934.PubMedCrossRef

36.

Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res. 2006;66(19):9385–92. doi:10.1158/0008-5472.CAN-06-0590.PubMedCrossRef

37.

Surace EI, Strickland A, Hess RA, Gutmann DH, Naughton CK. Tslc1 (nectin-like molecule-2) is essential for spermatozoa motility and male fertility. J Androl. 2006;27(6):816–25. doi:10.2164/jandrol.106.000398.PubMedCrossRef

38.

Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, et al. The tumor suppressor protein TSLC1 is involved in cell–cell adhesion. J Biol Chem. 2002;277(34):31014–9. doi:10.1074/jbc.M203620200.PubMedCrossRef

39.

Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene. 2004;23(33):5632–42. doi:10.1038/sj.onc.1207756.PubMedCrossRef

40.

Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res. 2002;93(6):605–9.PubMedCrossRef

41.

Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, et al. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res. 2002;62(18):5129–33.PubMed

42.

Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007;103(3):283–91. doi:10.1007/s10549-006-9377-7.PubMedCrossRef

43.

Fu L, Gao Z, Zhang X, Tsang YH, Goh HK, Geng H, et al. Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma. Int J Cancer. 2009;124(7):1572–8. doi:10.1002/ijc.24123.PubMedCrossRef

44.

Heller G, Fong KM, Girard L, Seidl S, End-Pfutzenreuter A, Lang G, et al. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene. 2006;25(6):959–68. doi:10.1038/sj.onc.1209115.PubMedCrossRef

45.

Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, et al. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer. 2012;15(6):130. doi:10.1002/ijc.26160. 1329-1337.

46.

Williams YN, Masuda M, Sakurai-Yageta M, Maruyama T, Shibuya M, Murakami Y. Cell adhesion and prostate tumor suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4. Oncogene. 2006;25:1446–53.PubMedCrossRef

47.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28.PubMed

48.

Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7(1):21–33. doi:10.1038/nrg1748.PubMedCrossRef

49.

Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988–93. doi:10.1038/nrc1507.PubMedCrossRef

50.

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54. doi:10.1056/NEJMra023075.PubMedCrossRef

51.

Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2005;11(8):2954–61. doi:10.1158/1078-0432.ccr-04-2206.PubMedCrossRef

52.

Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, Pulst SM. The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the “open” conformation and suppresses cell growth and motility. Hum Mol Genet. 2001;10(8):825–34.PubMedCrossRef

53.

Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol. 2000;59(10):872–9.PubMed

54.

Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M, et al. Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene. 1998;17(26):3499–505. doi:10.1038/sj.onc.1202258.PubMedCrossRef

55.

Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, et al. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer. 2004;40(3):190–203. doi:10.1002/gcc.20034.PubMedCrossRef

56.

Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58(1):95–101.PubMed

57.

Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL. Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs. 2003;14(3):193–202. doi:10.1097/01.cad.0000060628.27490.28.PubMedCrossRef

Title: Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells
Authors: Yajie Zhang
Ruobing Xu
Guiqin Li
Xiaobin Xie
Jie Long
Hongyan Wang
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0452-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Differential gene expression of Wnt signaling pathway in benign, premalignant, and malignant human breast epithelial cells

Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells

PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group

Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model

miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway

Associations of non-metastatic cells 1 gene polymorphisms with lymph node metastasis risk of gastric cancer in Northern Chinese population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer